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Key findings 
Rating the certainty of the body of evidence (quality of evidence or confidence in estimates) 
of test accuracy studies differs conceptually but shares the fundamental logic for the 
domains risk of bias and indirectness of the GRADE approach for intervention, prognostic or 
other studies.  
What this adds to what is known? 
Questions about the relative merit of alternative testing strategies in clinical and public 
health require framing in terms of health outcomes. Evidence evaluation will often, 
however, begin with an evidence synthesis - ideally a systematic review or health 
technology assessment - and rating of test accuracy, and subsequently move to evaluation 
of the evidence linking test accuracy to patient-important and population outcomes. We 
describe examples for how GRADE has been applied to test accuracy studies in Cochrane 
and other reviews and World Health Organization and other guidelines focusing on risk of 
bias and indirectness in part 1 of this article.  
What are the implications, what should change now? 
Investigators interested in using the GRADE for diagnostic and other healthcare related tests 
should consider the guidance offered in this article about how to evaluate research that 
focuses on the impact of tests, specifically from test accuracy studies in the context of risk of 
bias and indirectness. We provide examples for how to separate indirectness on a 
population, test intervention, test comparison and outcome levels.   
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Abstract 
Objectives: This article provides updated GRADE guidance about how authors of systematic 
reviews and health technology assessments (HTA) and guideline developers can assess the 
results and the certainty of evidence (also known as quality of the evidence or confidence in 
the estimates) of a body of evidence addressing test accuracy (TA).   
Study Design and Setting: We present an overview of the GRADE approach and guidance for 
rating certainty in TA in clinical and public health and review the presentation of results of a 
body of evidence regarding tests. Part 1 of the two parts in this 21
st
 guidance article about 
how to apply GRADE focuses on understanding study design issues in test accuracy, provide 
an overiew of the domains and describe risk of bias and indirectness specifically. 
Results: Supplemented by practical examples, we describe how raters of the evidence using 
GRADE can evaluate study designs focusing on tests and how they apply the GRADE domains 
risk of bias and indirectness to a body of evidence of TA studies.   
Conclusions:  Rating the certainty of a body of evidence using GRADE in Cochrane and other 
reviews and World Health Organization and other guidelines dealing with in TA studies 
helped refining our approach. The resulting guidance will help applying GRADE successfully 
for questions and recommendations focusing on tests. 
 
Key words:  GRADE, diagnosis, tests, test accuracy, certainty of evidence, diagnostic 
accuracy 
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GRADE guidelines: 21 part 1. Study design, risk of bias and indirectness in rating the 
certainty across a body of evidence for test accuracy  
 
1.0 Introduction 
Previous GRADE articles described the reasons for decreasing and increasing the certainty of 
a body of evidence; how to perform and present an overall rating of the evidence; how to 
use evidence to move to decisions and recommendations; guidance for addressing missing 
outcome data and multiple intervention comparisons; rating evidence regarding values and 
preferences and the use of GRADE in the context of environmental and public health 
questions and rapid guidance.(1-21) Clinicians and policy-makers also face choices regarding 
diagnostic, monitoring or screening tests or test strategies, choices that if made optimally 
will result in net benefit for people or patient-important outcomes and overall net desirable 
consequences.(9-11)  
 
However, questions related to tests present unique challenges. Here, we describe how 
authors of systematic reviews and health technology assessments (HTAs) and guideline 
developers using GRADE can address the certainty (in this series also referred to as quality 
or confidence) in a body of evidence from test accuracy (TA) studies, and present the results 
of their assessment.  These articles supplement our previous work addressing GRADE for 
tests.(11, 22, 23) Part 1 of the two parts in this 21
st
 guidance article is about how to apply 
GRADE focuses on understanding study design issues in TA, provide an overiew of the 
domains and describe risk of bias and indirectness specifically. Part 2 focuses on the 
domains imprecision, inconsistency, publication bias, considerations about upgrading and 
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guidance about how to present this information in GRADE summary of findings (SoF) tables 
.(24) 
 
2.0 Establishing the purpose of a test 
Health care providers use tests that are often referred to as “diagnostic” – including signs 
and symptoms, imaging, biochemistry, psychological assessments, pathology, microbiology 
and other tests – to guide management and for other purposes.(25) Guideline groups and 
authors of systematic reviews or HTAs addressing tests must define the purpose and role of 
the tests in their particular context. This process should begin with determining the existing 
test or diagnostic pathway – or pathways – for the patient presentation and identify the 
adverse outcomes that will arise from direct complications of invasive tests or the 
consequences of true positive, e.g. overdiagnosis, true negatives, false positive and false 
negative test results. Knowing these adverse outcomes may suggest if an alternative test or 
strategy that is less invasive or with superior diagnostic properties may result in greater net 
health benefit which we discuss in more detail in section 2.3. and elsewhere.(26)  
The purpose of a test under consideration may be for screening, risk assessment, diagnosis, 
prognosis, staging, monitoring, or surveillance. The role of a test may be for (i) replacement 
(i.e., with tests with less burden, invasiveness, cost, or superior accuracy), (ii), triage (i.e., to 
minimize use of an invasive or expensive test), (iii) add-on (i.e., to further enhance 
diagnostic accuracy beyond the existing diagnostic pathway) or (iv) parallel or combined 
testing (i.e. tests that health professionals order and evaluate together to inform a 
particular diagnosis, table 1).(27-29)  
 
2.1 Positive and negative tests, single tests and test strategies 
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While some tests report positive and negative results (e.g., pregnancy, HIV infection), other 
tests report their results as ordinal (e.g., Glasgow coma scale, mini-mental status 
examination) or continuous variables (e.g., serum ferritin, troponin, hemoglobin), with 
increasing likelihood of disease or adverse health effects as the test results become more 
extreme. For simplicity, in this discussion we generally assume an approach that ultimately 
categorizes test results as positive or negative, in part to describe presence or absence of a 
target condition. This also recognizes that many tests ultimately lead to treat or do not treat 
decisions based on the “positive or negative” result of the test. 
 
Clinicians, public health workers and researchers often administer tests as a strategy or 
package composed of several tests. For example, in managing patients with a diagnosis of 
cervical intraepithelial neoplasia - a precursor of cervical cancer - based on visual inspection 
with acetic acid (VIA), clinicians may proceed to treatment directly or further test for human 
papilloma virus (HPV) to increase the probability of neoplasia being present.(30, 31) A 
testing strategy may also use an initial sensitive but non-specific test which, if positive, is 
followed by a more specific test (e.g., testing for HIV includes the use of an ELISA test 
followed by quantitative HIV RNA determination for those with positive ELISA test results). 
Thus, one can often think of evaluating or recommending a test strategy rather than a single 
test, and usually it is a recommendation based on a comparison to alternative test 
strategies. 
 
2.2. Clear healthcare and clinical questions 
Clearly establishing purpose and role of a test or test strategy will lead to the identification 
of sensible healthcare questions that, similar to other management problems, have four 
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components: population, intervention tests (or strategies), comparison test (or strategy), 
and the outcomes of interest.(32, 33) Labeling testing as an intervention recognizes the 
fundamental principle that test results will lead to specific management decisions and those 
decisions will influence outcomes. Box 1 shows three examples of questions about the use 
of tests to which we will refer in this and other articles in this series.(11, 26)  
Box 1. Examples of questions about tests 
Example 1: In women at risk for cervical intraepithelial neoplasia (CIN) in low and middle-
income settings, what is the impact of testing for presence of human papilloma virus 
(HPV) instead of VIA on patient and population important outcomes?(30) 
Population: women at risk of cervical cancer in low and middle-income countries 
Role: replacement test 
Setting: clinics in low and middle income countries 
Intervention: one-time screening with HPV and treatment for cervical intraepithelial 
neoplasia 
Comparison: VIA and treatment for cervical intraepithelial neoplasia  
Purpose and role of test: diagnosis and replacement of no testing  
Outcomes: death from cervical cancer, cervical cancer incidence, CIN recurrence, major 
bleeding, premature delivery, infertility, major and minor infections, unnecessary treatment 
and burden, cervical cancer detection during screening 
 
Example 2 (short form focusing on patient outcomes): In patients suspected of cow’s milk 
allergy (CMA), what is the impact of skin prick tests versus an oral food challenge with 
cow’s milk on mortality from allergic reactions, allergic reactions, development of other 
allergies.(34) 
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Participants: patients suspected of CMA  
Role: replacement test  
Setting: specialized clinics 
Index (new) test (intervention): IgE skin prick test  
Reference test (comparison): no IgE skin prick test 
Outcome: test accuracy with health outcome descriptors for the test positives and negatives 
Example 3 (test accuracy focused): In patients presumed to have tuberculous (TB) 
meningitis, what is the accuracy of Xpert – a nucleic acid amplification test (NAAT) – for 
the diagnosis of TB meningitis? 
Participants: patients suspected of having TB meningitis 
Prior testing: patients who received Xpert testing may first have undergone a health 
examination (history and physical examination) and possibly a chest radiograph 
Role: replacement test for usual practice 
Settings: primarily tertiary care centres (the index test was run in reference laboratories) 
Index (new) test (intervention): Xpert  
Reference test (comparison): culture 
Outcome: test accuracy 
 
The example of using HPV instead of VIA for screening for cervical precancerous lesions in 
Box 1 illustrates one common rationale for a new test: test replacement to avoid a slightly 
more invasive alternative for a condition amenable to effective treatment.(27) Such a new 
test would only need to be as accurate as the existing test to demonstrate greater net 
benefit (by lowering burden and harm). This assumes that the new test similarly categorizes 
patients at the same stage of disease and that the consequences of the test result, i.e. 
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management decisions and outcomes, are similar. However, these scenarios are not 
common. 
 
2.3. Estimating impact on people or patient-important outcomes 
Recommendations regarding use of tests require inferences about the consequences of 
falsely identifying patients as having or not having the disease, but also consequences of 
correct test results that do not lead to net benefit (e.g. overdiagnosis or lack of treatment 
effects). If a test fails to improve people-important outcomes (in the context of population 
or public health) or patient-important outcomes (in the context of clinical care) there is no 
reason to use it, whatever its accuracy.  We will refer to the consequences of alternative 
testing strategies on these outcomes as “test impact”. 
 
Dealing first with TA, ascertainment of TA relies on the presence of a gold, reference or 
criterion standard that is used to establish if the target disease is present or absent.  Often, 
an error-free gold standard is unavailable. Moreover, constructs of disease may change (e.g, 
in oncology, with a superior molecular understanding of the underlying pathologies, or 
Alzheimer’s dementia). We will use the term gold standard here as representing the 
“perfect” approach to defining or diagnosing the disease or condition of interest, even if the 
approach is theoretical or hypothetical. We will use the term “reference standard” for the 
test or test strategy that is the current best and accepted approach to making a diagnosis 
against which a comparison with an “index test” (the test under consideration) may be 
made. A reference standard can consist of the gold standard, but more likely represents a 
less than ideal reference standard – in which case one could compare the accuracy of the 
reference standard to the gold standard, if the gold standard is feasible to perform. 
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However, by definition accuracy cannot be superior to the gold standard.  Also by definition, 
acceptance of a new gold standard, for instance as a result of scientific development, 
requires consensus, proof of added benefit and acceptance rather than only demonstration 
of better TA.  
 
Given the importance of focusing on outcomes that are important to people and the 
uncertainties related to reference and gold standards and the relation between tests and 
patient or population consequences, the best way to assess a test strategy is a test-treat 
randomized controlled trial design in which investigators allocate patients to experimental 
or control testing approaches and measure mortality, morbidity, symptoms, quality of life 
and resource use.(35) 
 
Figure 1a describes the fundamental elements of study designs of test accuracy studies and 
the ideal test impact study – that is, a randomized trial of alternative testing and 
management strategies.  Various randomized designs leading to high confidence in 
estimates exist, including interaction designs that help to directly determine the impact, 
both positive and negative, of a test on health outcomes.(28, 36, 37) When test impact 
studies – ideally RCTs but also observational studies – comparing alternative test strategies 
with direct assessment of patient-important outcomes are available (Figure 1a), guideline 
panels can use the GRADE approach for other interventions described in prior GRADE 
articles.(1, 38)  
All too frequently, however, management decisions depend on evidence obtained in 
separate steps. Figure 1b illustrates a generic study structure that guideline developers 
often have to use to evaluate the impact of testing.(22) 
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Insert Figure 1 (a) & (b) approximately here 
 
This latter approach links evidence by bringing together TA estimates with evidence 
regarding subsequent management and the treatment effects associated with that 
management to model the impact of TA results on health outcomes.(22, 39) In that 
situation, TA may be considered a surrogate outcome for people-important benefits and 
harms.(25) Those developing recommendations must make these inferences, and the 
underlying assumptions about the evidence on which the inferences are based, transparent.   
 
The key questions when using TA as a surrogate are: (i) what outcomes can those with 
positive and negative test results expect based on the likely subsequent management?; (ii) 
what will be the relative impact of the testing strategies under consideration on the number 
of false negatives (people with the disease who are missed) or false positives (people 
without the disease who are incorrectly considered as having the disease)?; and (iii) how 
similar or different are people to whom the test is applied  in practice (and classified by the 
alternative testing strategies) to those evaluated in TA studies? An alternative is to abjure 
making explicit inferences, to provide guidance solely on the basis of TA information and 
point out that direct evidence for a people-important benefit is lacking – perhaps with a 
recommendation for generation of such evidence.(40) 
 
2.4. Indirect evidence and impact on patient-important outcomes 
Consequences of tests typically go beyond the benefits and harms that one usually 
considers in assessing therapeutic interventions.  We previously described the issues with 
GRADE detailed series - JCE  
GRADE Guidelines: Diagnosis I                                              Version 20191119 revised 
GRADE Article 21 diagnosis_I  part 1 20191119 revised clean.docx  13 
 
highly accurate genetic testing for Huntington’s chorea, a condition that currently cannot be 
cured, may provide either welcome reassurance that a patient will not suffer from the 
condition or the ability to plan for the future knowing that the patient may sadly fall 
victim.(22) In this case, the ability to plan the future is analogous to the usual outcomes of 
benefit (e.g. reducing mortality) and harm (e.g. adverse effects), and the benefits of 
planning require trading off against the downsides of receiving an early diagnosis. In such 
instances - as in most others - guideline panels would review the evidence and they might 
find that the evidence does not equivocally support testing, i.e. providing net benefit, 
because differences in values and preferences are likely to play an important role in making 
this decision.(41-43)  
 
Thus, inferring from accuracy data that a diagnostic test or strategy improves patient-
important outcomes usually requires access to effective management and the values that 
relate to the anticipated outcomes.(25) In GRADE guidance 22 in this series, we will discuss 
these issues in greater detail. Now we will focus on the assessment of certainty of evidence 
TA. 
 
2.5 Judgment about the certainty of the underlying evidence 
We will use the systematic review by Kohli et al. (44) to demonstrate how judgements are 
made (an online supplement provides additional examples). This review looked at Xpert
®
 
MTB/RIF (Xpert), a rapid, automated, nucleic acid amplification assay that is widely used for 
simultaneous detection of Mycobacterium tuberculosis complex and rifampicin resistance in 
sputum specimens. (44) Our focus is on evidence regarding the usefulness of the test in the 
diagnosis of tuberculous meningitis (Example 3, Box 1).   
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3.0 Certainty of the evidence from TA studies  
In the GRADE approach, appropriately designed TAs (see below) start as high certainty 
evidence. However, in the context of providing evidence to support guideline 
recommendations or decisions focusing on these studies in isolation will usually result in low 
or very low certainty supporting the decision due to indirectness of evidence because TA is a 
surrogate for the impact of testing on patient-important outcomes. That is, if those 
developing recommendations or making decisions do not identify and assess the linked 
evidence, they should rate down the evidence supporting a decision or specifically 
describing that they only considered the certainty of the TA studies (see article 22 in this 
series (26)), Table 2 lists factors that influence the certainty of a body of evidence from TA 
studies.  
 
Insert Table 2 approximately here 
 
In the tuberculous meningitis example, all studies were cross-sectional studies appropriately 
designed to evaluate test accuracy.(44) The initial rating for the body of evidence for test 
accuracy studies is high. 
  
3.1. Certainty of the evidence for TA - risk of bias (limitations in the detailed study design 
and execution) 
Researchers have developed several instruments for the evaluation of risk of bias in TA 
studies.(45-47) For example, a selection of the items of the QUADAS-2 instrument allow 
transparent assessment of risk of bias based on the features shown in Table 3. (48)  
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Insert Table 3 approximately here 
 
Appropriate TA studies include patients with an uncertain diagnosis who are representative 
of the target population. Such studies should preferentially enrol consecutive or randomly 
selected patients in whom diagnostic uncertainty exists – that is, the sort of patients to 
whom clinicians would apply the test in the course of regular clinical practice. If studies fail 
this criterion – and for example enrol severely affected patients and healthy controls – the 
apparent accuracy of a test is likely to be misleadingly high.(49, 50)  
 
3.1.1. Examples of risk of bias (limitations in the detailed study design and execution) 
judgments 
Appropriate TA studies also involve a comparison between one or more tests under 
consideration, where all tests are measured against the same reference standard. 
Investigators’ failure to apply the reference standard in all patients increases the risk of bias. 
The risk of bias may be higher if a composite reference standard is used and the included 
studies use different ways of ascertaining the presence or absence of a target condition.  
The risk of bias is further increased if those who conduct or interpret the index test are 
aware of the results of the reference standard or vice versa.  
 
In our example of Xpert for the diagnosis of tuberculous meningitis, using QUADAS-2, risk of 
bias was low for the patient selection, index test, and flow and timing domains. For the 
reference standard domain, of 29 total studies, four (14%) studies had unclear risk of bias. In 
these four studies, specimens underwent decontamination and it was unclear whether this 
process affected the reference standard.  However, since most studies had low risk of bias, 
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the authors did not downgrade (Figure 2).(44)  In another systematic review, using the 
original QUADAS instrument (QUADAS-2 was introduced in 2011), Steingart and colleagues 
evaluated the risk of bias of studies of commercial serological tests for the diagnosis of 
active pulmonary and extrapulmonary tuberculosis.(51) Most of the 67 included studies did 
not recruit participants in a random or consecutive manner, and only approximately 50 
studies reported blinded interpretation of the serological test result. The authors, therefore, 
downgraded the certainty of the evidence for risk of bias.  
 
3.2. Certainty of the evidence – applicability and indirectness  
Direct evidence comes from research that closely addresses the population we are 
interested in, compares the interventions in which we are interested and measures the 
outcomes important to people or patients. Judging indirectness - synonymous with 
applicability, transferability, generalizability, translatability and external validity of the 
evidence - includes indirectness related to the downstream consequences.   As with 
therapeutic interventions, indirectness must be assessed in relation to the population (and 
setting), the intervention (the new or index test), the comparator (another test), and 
outcomes. We will deal with indirectness related to test outcomes and their impact in more 
detail in article 22 in this series.(26) 
 
3.2.1. Population indirectness 
The chosen patient sample may cause indirectness. Studies may also provide indirect 
evidence if the target condition of the population is not the same in the studies compared to 
the question asked and an interaction between the population and test performance is 
expected. Population indirectness does not only relate to the disease spectrum in the 
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included patients, but also to the setting in which the research was done, prior testing done 
on the patients, or possible referral paths. For instance, a judgment of indirectness of the 
population can result from using a different test setting (e.g. patients seen in an emergency 
department may differ from patients seen in a general practitioner office). Another example 
may be when guidance is needed for testing in children and the available evidence is based 
upon studies with adults, or mixed age populations.  Prevalence or pretest probability may 
be a guide to judge whether there is indirectness in the population: is the average 
prevalence in the available evidence comparable to what is found in practice? Investigators 
can explore the influence of all these sources of variability in sensitivity analyses.   
 
3.2.2. Intervention(s) or Index test(s) indirectness 
Indirectness in the intervention or index test domain may occur when, for example, tests in 
the studies or reviews found have been implemented with slightly different standards than 
the standards used in practice, e.g. a country, specialty or health plan, for which the 
guidance is intended. Different cut-off values or thresholds between settings may lead to 
indirectness (and often explain inconsistency in sensitivity analyses). Different settings may 
also introduce intervention indirectness if the test is applied in an emergency department as 
opposed to a primary care setting (e.g., due to specimen transport or personnel 
qualifications in emergency departments as opposed to a general practitioner’s office).  
Specimen transfer issues become particularly salient if mechanistic studies have 
demonstrated that transport conditions affect test performance (e.g. transfer at room 
temperature versus on ice may induce changes in a serum level of a biomarker). This type of 
indirectness incorporates concepts of technical variability and test-retest and operator 
reliability.   
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3.2.3. Comparator(s) indirectness 
Any question about tests will have a comparison at its basis. Unfortunately, accuracy studies 
often focus on one test only. For example, in a question focusing on the accuracy of D-dimer 
for pulmonary embolism the comparison may be between different D-dimer tests (TA at 
different D-dimer levels), between clinical signs and symptoms (standard care; no testing) 
and no D-dimer (does d-dimer have a higher TA than signs and symptoms alone), or 
between another test and D-dimer. That means that in case of an explicit comparison with 
another test or in the key question, this comparator will almost always cause some degree 
of indirectness in the comparator domain. Also, if comparative accuracy studies compared 
our test of interest with another test that we are not interested in as our comparator, then 
that may lead to indirectness. Second, if the clinical question is about the choice between 
two tests, neither of which is a reference standard, the two tests may be compared directly 
against the reference test in the same study. For instance, in the example of comparing HPV 
with VIA all studies independently utilized both tests and compared it against a reference 
standard (colposcopy with biopsy) to evaluate the incremental or relative accuracy, 
sometimes expressed as difference in accuracy or comparative accuracy (Figure 3).(31) 
Alternatively, one might make an indirect comparison based on separate studies in which 
each test was compared against the reference standard and usually rate down for indirect 
comparisons.  
 
3.2.4. Outcomes and outcome measures 
TA as an outcome will nearly always cause indirectness for guideline developers and other 
decision makers because the recommendations and decisions should be based upon 
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intervention outcomes that follow from the test results when the available evidence often 
only includes accuracy as an outcome.  
If the key question focuses on diagnostic TA and authors of a systematic review rate the 
certainty in accuracy outcomes, then there may be no indirectness between the available 
evidence (accuracy studies) and the desirable outcomes (accuracy measures). The 
indirectness related to people-important outcomes should then be assessed by those using 
the review for recommendations or decisions (see GRADE guidance on evidence to decision 
frameworks and linked evidence (11, 26)). However, there may still be indirectness in the 
outcome itself, for example because of a different definition of the condition of interest in 
studies compared to the condition in the systematic review author’s, HTA author’s or 
guideline developer’s question of interest.   
 
3.2.5. Examples for indirectness 
In the tuberculous meningitis example, the three included studies engendered concern 
about indirectness because patients were evaluated as inpatients in tertiary care centres 
but tuberculous meningitis is a medical emergency often treated in primary and secondary 
care hospitals. The raters judged the patients in tertiary care centers to be similar to those 
in  secondary and primary care settings and did not rate down for indirectness. For the index 
and reference test domains, the authors considered most studies to have no serious 
concern because both the index test was performed as in routine clinical practice. With 
regards to the outcomes, the raters did not evaluate the indirectness related to the 
downstream health consequences in the review and this was left to the decision makers, 
which we deal with in the next article in this series.(26) Table 4 demonstrates how raters 
can structure their judgments transparently. 
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Insert Table 4 approximately here 
5.0 Conclusion 
The GRADE approach to rating the certainty of evidence for TA is comprehensive and 
transparent.  We have presented an overview of this approach and operatonialized the first 
two of the GRADE domains, risk of bias and indirectness, to rate the certainty in a body of 
evidence for TA studies. They have been applied in many systematic reviews and guidelines.  
In part 2 of this GRADE guidance about rating the certainty of evidence in tests, we will 
focus on the domains inconsistency, imprecision, rating up and presentation of findings 
related to TA.(24) In GRADE guidance 22 in this series we will describe how the information 
from test accuracy can inform the development of recommendations, based on the 
recognition that test results can be surrogate markers for patient important outcomes.(26)  
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Replacement A new test might substitute an old one, because it is more accurate, less 
invasive, less risky or uncomfortable for patients, organizationally or 
technically less challenging, quicker to yield results or more easily 
interpreted, or less costly. 
Triage A new test is added before the existing diagnostic pathway and only 
patients with a particular result on the triage test continue the testing 
pathway; triage tests are not necessarily more accurate but usually 
simpler and less costly. 
Add-on A new test is added after the existing diagnostic pathway and may be used 
to limit the number of either false positive or false negative results after 
the existing diagnostic pathway; add-on tests are usually more accurate 
but otherwise less attractive than existing tests. 
Parallel or 
combined 
A new test which is intended to be used concurrently with an existing test. 
Both, the results of the existing and the parallel test are utilized for 
making a diagnosis and to determine management.  
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Table 2. Factors that decrease the certainty of evidence for studies of test accuracy and how 




Factors that determine and can decrease 
the certainty of evidence 
Explanations and how the factor may differ from the certainty of evidence for other 
interventions 
Study design Different criteria for accuracy studies 
Cross-sectional or cohort studies in patients with diagnostic uncertainty and direct 
comparison of test results with an appropriate reference standard (best possible 
alternative test strategy) start as high certainty but may be rated down to moderate, low 
or very low depending on other factors. 
Risk of bias (limitations in study design and 
execution) 
Different criteria for accuracy studies  
• Representativeness of the population that was intended to be sampled. 
• Independent comparison with the best alternative test strategy. 
• All enrolled patients should receive the new test and the best alternative test 
strategy. 
• Diagnostic uncertainty should be given. 
• Is the reference standard likely to correctly classify the target condition? 
• QADAS2 is an acceptable tool. 
Indirectness and applicability 
Patient population, index test, comparison 




Similar criteria to therapy questions 
The certainty of evidence can decrease if there are important differences between the 
populations studied and those for whom the recommendation is intended (in prior 
testing, the spectrum of disease or co-morbidity); if there are important differences in 
the tests studied and the diagnostic expertise of those applying them in the studies 
compared to the settings for which the recommendations are intended; or if the tests 
being compared are each compared to a reference (gold) standard in different studies 
and not directly compared in the same studies. 
 
Similar criteria to therapy questions 
Guideline groups assessing diagnostic tests often face an absence of direct evidence 
about impact on patient-important outcomes. They must make deductions from 
diagnostic test studies about the balance between the presumed influences on patient-
important outcomes of any differences in true and false positives and true and false 
negatives in relationship to test complications and costs. Therefore, accuracy studies 
typically provide low quality evidence for making recommendations due to indirectness 
of the outcomes, similar to surrogate outcomes for treatments. Guideline groups should 
therefore identify linke evidence that informs about the consequences of the accuracy 
outcomes (26) 
Important Inconsistency in study results Similar criteria to therapy questions 
For accuracy studies unexplained inconsistency in sensitivity, specificity or likelihood 
ratios (rather than relative risks or mean differences) can lower the certainty of evidence. 
Imprecise evidence Similar criteria to therapy questions 
For accuracy studies wide confidence intervals for estimates of test accuracy, or true and 
false positive and negative rates can lower the certainty of evidence. 
High probability of Publication bias Similar criteria to therapy questions 
A high suspicion of publication bias (e.g., evidence only from small studies supporting a 
new test, or asymmetry in a funnel plot) can lower the certainty of evidence. 
Upgrading for dose effect, large effects 
residual plausible bias and confounding 
Similar criteria to therapy questions 
For all of these factors, methods have not been fully developed. However, determining a 
dose effect (e.g., increasing levels of anticoagulation measured by INR increase the 
likelihood for vitamin K deficiency or vitamin K antagonists). A very high likelihood of 
disease (not of patient-important outcomes) associated with test results may increase 
the certainty of the evidence. However, there is some disagreement if and how dose 
effects play a role in assessing the certainty of evidence in TA studies. 
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Table 3. Risk of bias criteria of diagnostic accuracy studies derived from QUADAS-2  
(48)  
Domain Patient Selection Index Test Reference Standard Flow and Timing 
Description Describe methods of patient 
selection 
Describe included patients 
(previous testing, 
presentation, intended use of 
index test,  and setting) 
Describe the index test and 
how it was conducted and 
interpreted 
Describe the reference 
standard and how it was 
conducted and interpreted 
Describe any patients who 
did not receive the index 
tests or reference standard 
or who were excluded  
from the 2 X 2 table (refer 
to flow diagram) 
Describe the interval and 
any interventions between 





(yes, no, or 
unclear) 
Was a consecutive or random 
sample of patients enrolled? 
Was a case–control design 
avoided? 
Did the study avoid 
inappropriate exclusions? 
 
Were the index test results 
interpreted without know- 
ledge of the results of the 
reference standard? 
If a threshold was used, was 
it pre-specified? 
 
Is the reference standard likely 
to correctly classify the target 
condition? 
Were the reference standard 
results interpreted without 
knowledge of the results of 
the index test? 
 
Was there an appropriate 
interval between index 
tests and reference 
standard? 
Did all patients receive a 
reference standard? 
Did all patients receive the 
same reference standard? 
Were all patients included 
in the analysis? 
 
Risk of bias 
(high, low, 
or unclear) 
Could the selection of 
patients have introduced 
bias? 
Could the conduct or 
interpretation of the index 
test have introduced bias? 
Could the reference standard, 
its conduct, or its 
interpretation have introduced 
bias? 
Could the patient  flow 
have introduced  bias? 
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Table 4. Indirectness judgment across the body of evidence for true positives. 
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Figure 1a and 1b. Basic designs to evaluate tests 
 
Figure 1 (legend). Two generic ways to evaluate the impact of a test or diagnostic strategy: a) Patients 
are randomized to either a new test or strategy or to an old test or strategy. Those with a positive test 
(cases detected) are randomized (or were previously randomized) to receive the best available 
management (second step of randomization for management not shown in this figure). Investigators 
evaluate and compare patient-important outcomes in all patients in both groups.(27) b) Patients receive 
both a new test and a reference test (it often, however, is the old or comparator test or strategy). 
Investigators can then calculate the accuracy of the test compared to the reference test (first step). To 
make judgments about patient-impact of this test information, patients with a positive test (or strategy) 
in either group are (or have been in previous studies) submitted to treatment or no treatment; 
investigators then evaluate and compare patient-important outcomes in all patients in both groups 
(second step). 
Example for Figure 1a - B-type natriuretic peptide for heart failure 
Randomized controlled trials (RCTs) that explored a diagnostic strategy guided by the use of B-type 
natriuretic peptide (BNP) – designed to aid diagnosis of heart failure – compared with no use of BNP in 
patients presenting to the emergency department with acute dyspnea.(52, 53)  As it turned out, the 
group randomized to receive BNP spent a shorter time in the hospital at lower cost with no increased 
mortality or morbidity. 
Example for Figure 1b - non-contrast helical CT for urolithiasis 
Consistent evidence from well-designed studies demonstrates fewer false negative results with non-
contrast helical CT than with intravenous pyelography (IVP) in the diagnosis of suspected acute 
urolithiasis.(54)  However, the stones in the ureter that CT detects but IVP “misses” are smaller, and 
hence are likely to pass more easily.  Since RCTs evaluating the outcomes in patients treated for smaller 
stones are not available, the extent to which reduction in cases that are missed (false negatives) and 
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Figure 2. Example of a risk of bias assessment using QUADAS2- from for the use of 
Xpert in tuberculosis (44)  

































Figure 2 legend. Figure 2a. Risk of bias graph: review authors' judgements about 
each domain presented as number of studies and percentages across included 
studies. Figure 2b. Risk of bias review authors' judgements about each domain for 
each included study. This risk of bias for the total 66 studies not restricted to 
tuberculous meningitis included in the review.
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Figure 3. Example of expressing comparative accuracy of two tests against a reference test. 
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Domain (original question asked Description Judgment - Is the evidence sufficiently direct? 
Population: Three studies had high concern 
because patients were evaluated as 
inpatients in tertiary care centres; 
however, we recognize this is how 




                                            
 
 
Yes   Probably yes    Probably no   No 
Intervention: [intervention] For the index and reference test 
domains, we considered most 
studies to have low concern for 
applicability. 
                                            
 
Yes   Probably yes    Probably no   No 
Comparator: [comparison] For the index and reference test 
domains, we considered most 
studies to have low concern for 
applicability. 
                                            
 
Yes   Probably yes    Probably no   No 
Direct comparison Yes.                                             
 
Yes   Probably yes    Probably no   No 
Outcome: TP No concerns for test accuracy 
ratings, indirectness related to 
patient outcomes is not rated here in 
the assessment of certainty that 
focuses on accuracy alone. 
 
 
                                            
 
Yes   Probably yes    Probably no   No 
Final judgment about indirectness across domains:  
                                                           
 
No indirectness Serious indirectness Very serious indirectness 
 
Key findings 
Rating the certainty of the body of evidence (quality of evidence or confidence in estimates) of 
test accuracy studies differs conceptually but shares the fundamental logic for the domains risk 
of bias and indirectness of the GRADE approach for intervention, prognostic or other studies.  
What this adds to what is known? 
Questions about the relative merit of alternative testing strategies in clinical and public health 
require framing in terms of health outcomes. Evidence evaluation will often, however, begin 
with an evidence synthesis - ideally a systematic review or health technology assessment - and 
rating of test accuracy, and subsequently move to evaluation of the evidence linking test 
accuracy to patient-important and population outcomes. We describe examples for how GRADE 
has been applied to test accuracy studies in Cochrane and other reviews and World Health 
Organization and other guidelines focusing on risk of bias and indirectness in part 1 of this 
article.  
What are the implications, what should change now? 
Investigators interested in using the GRADE for diagnostic and other healthcare related tests 
should consider the guidance offered in this article about how to evaluate research that focuses 
on the impact of tests, specifically from test accuracy studies in the context of risk of bias and 
indirectness. We provide examples for how to separate indirectness on a population, test 
intervention, test comparison and outcome levels. 
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